Gut and liver
118 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| AC-101 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Adalimumab-800CW + Fluorescence Imaging for inflammatory bowel diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Alginos Oral Suspension for esophagitis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Anaprazole + Rabeprazole placebo for esophagitis, peptic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| aSMDC for fecal incontinence | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atezolizumab for fatty liver | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATG + CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System + Prednisone/Methylprenisolone + Total Body Irradiation + RITUXIMAB + CLOFARABINE + Melphalan + PALIFERMIN for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atorvastatin calcium trihydrate for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD7798 for crohn disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Baclofen for liver diseases, alcoholic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Berberine ursodeoxycholate for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Bevacizumab + atezolizumab for fatty liver | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bezlotoxumab for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bezlotoxumab for crohn disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood Sample + Cerebrospinal Fluid (CSF) Sample + Chemotherapy Drug, Cancer - Physician's Choice + Non-Investigational Surgical Resection + Radiotherapy (RT) + Tumor Tissue Sample + Temozolomide for pyloric stenosis, hypertrophic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brivekimig for crohn disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bv+r-chp for pyloric stenosis, hypertrophic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for liver cirrhosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Chemically induced pluripotent stem cells biological Artificial Liver for liver failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combination of Neostigmine and Glycopyrrolate + I-Box by Dynatronics for fecal incontinence | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combination of Neostigmine and Glycopyrrolate + I-Box by Dynatronics for neurogenic bowel | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Curcumin for gastritis, atrophic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CYTARABINE + Azacitidine + Venetoclax for pyloric stenosis, hypertrophic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Digital Intelligent Tongue-Pressure Biofeedback Resistance Training for deglutition disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donor Fecal Microbiota Transplantation for irritable bowel syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DR10624 Injection for non-alcoholic fatty liver disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DR10624 Injection for pancreatitis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Duvakitug for colitis, ulcerative | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ECC0509 for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ECC0509 + ECC4703 for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ECC4703 for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Efruxifermin for non-alcoholic fatty liver disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EGEN-5784 (genetically engineered porcine liver) + metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx) for acute-on-chronic liver failure | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for non-alcoholic fatty liver disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Emvistegrast for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Epidural spinal cord stimulation for neurogenic bowel | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for fatty liver | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver cirrhosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ex vivo perfusion of six-gene-edited porcine liver + Multi-drug immunosuppressive therapy for liver failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Faecal microbiota transplantation for gastrointestinal hemorrhage | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Faecal microbiota transplantation for hepatitis, alcoholic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Faecal microbiota transplantation for liver cirrhosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbial Transplantation for colitis, ulcerative | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal microbiota for colitis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplantation for inflammatory bowel diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplantation for irritable bowel syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fenofibrate for liver cirrhosis, biliary | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fenofibrate in Combination With Ursodeoxycholic Acid for liver cirrhosis, biliary | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluconazole for crohn disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluorescence Imaging for inflammatory bowel diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FMT capsule for irritable bowel syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food Security Screening & Referral Program for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Golimumab for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Guselkumab for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Guselkumab for crohn disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| H021 Enteric-coated Tablets High-dose Group for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| H021 Enteric-coated Tablets Low-dose Group for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HepaCure for hepatitis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HepaCure for liver failure | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High dose Recombinant Trivalent Subunit Rotavirus Vaccine for gastroenteritis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HSK31679 for non-alcoholic fatty liver disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HU6 for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydrocortisone for pancreatitis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Indocyanine Green for biliary atresia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Infliximab for colitis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Infliximab for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| infliximab (IFX) infusion; azathioprine (AZA) caps for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| infliximab (IFX) placebo infusion; azathioprine (AZA) caps for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| INT-210 Capsule for colitis, ulcerative | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intermittent Reduced Calorie Diet (IRCD) for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intra-rectal botulinum toxin injections for fecal incontinence | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JNJ-78934804 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JP-1366 + placebo for non-erosive reflux disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| local co-administration of autologous ADIpose for crohn disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mandibular advancement Device for gastroesophageal reflux | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for gastroenteritis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mirikizumab for colitis, ulcerative | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| miRNA Biomarker-Guided Immunosuppression Minimization for liver diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Norucholic acid for cholangitis, sclerosing | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Obefazimod for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Obeticholic acid for fatty liver | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PALI-2108 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pancreatic enzyme capsules for exocrine pancreatic insufficiency | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pancreatic enzyme capsules for pancreatitis, acute necrotizing | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pegargiminase for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine-Topiramate for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PJ009 for short bowel syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for crohn disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo-to-match emvistegrast + Emvistegrast for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for non-alcoholic fatty liver disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy + TRYP-0082 for irritable bowel syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rabeprazole sodium for gastroesophageal reflux | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Risankizumab for crohn disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Saccharomyces cerevisiae for irritable bowel syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for non-alcoholic fatty liver disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| single FMT for colitis, ulcerative | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SNP-610 for non-alcoholic fatty liver disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Soy-tomato juice product + Will include a soy-tomato juice product to be consumed during the 4 week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed for pancreatitis, chronic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SPY001 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SPY001 + SPY002 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SPY001 + SPY003 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SPY002 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SPY002 + SPY003 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SPY003 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Standard Soy Milk for non-alcoholic fatty liver disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Stimulation for blood pressure with stand for neurogenic bowel | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Stimulation for blood pressure without stand for neurogenic bowel | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Stimulation for trunk and core without stand for neurogenic bowel | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Stimulation for trunk or core with stand for neurogenic bowel | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Survodutide for liver diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Survodutide for non-alcoholic fatty liver disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trametinib + DABRAFENIB for pancreatic diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcatheter tricuspid valve replacement for gastroesophageal reflux | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vedolizumab for colitis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vedolizumab for colitis, ulcerative | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vedolizumab for crohn disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Very-low calorie diet for fatty liver | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |